ATS Corporation

ATS Corporation

ATSAF
ATS CorporationUS flagOther OTC
44.25
USD
- -
- -
4.06BMarket Cap
ATS Corporation
ATSAF
(Other OTC)

Recent

price

44.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
ATS Corporation (TSX: ATS, OTC: ATSAF) is a global designer, manufacturer and provider of mission-critical factory automation solutions, including custom products and modular automation platforms, serving a diverse range of end markets such as life sciences, battery manufacturing, food and beverage, transportation, semiconductors, consumer products, energy, and clean technologies. The company offers customized automation solutions; turnkey systems including assembly, test, vision and material handling systems; standardized automation modules under brands like the OmniPlace family of autonomous mobile robots (AMRs), Sigma product line for cleanroom-compatible automation platforms, and FlexMation modular systems; and related services encompassing total factory control software, consulting, prototyping, engineering, deployment, maintenance, training, and lifecycle management. Founded in 1978 and headquartered in Cambridge, Ontario, Canada, ATS operates through three segments—Automation Systems Group, Automation Products Group, and Life Sciences Systems Group—with manufacturing facilities and sales offices across North America, Europe (including Germany, the UK, and Switzerland), and Asia (primarily China and India), targeting blue-chip customers like AstraZeneca, Panasonic, Nestle, General Motors, Intel, and Siemens. In recent developments, ATS completed the divestiture of its ASI Distribution business in March 2025 to focus on core automation growth; launched the next-generation OmniPlace AMR platform in 2024 to expand its robotics offerings; acquired Krones' Life Science business in late 2024, enhancing its aseptic filling capabilities for pharmaceuticals and biotech; formed a strategic partnership with Tesla in 2025 for battery manufacturing automation; and reorganized under new leadership following CEO Chris Jones' appointment in 2024 to drive expansion in high-growth sectors like electric vehicles and bioprocessing.

Company News

MCPAPIChat
  • ATS to Participate in the Stifel Summer Solstice Conference

  • ATS Q4 Earnings Call Highlights

  • ATS (ATS) Q4 Earnings Lag Estimates

  • ATS Reports Fourth Quarter Fiscal 2026 Results

  • Entravision: The Broadcaster That Quietly Became An Ad-Tech Company

  • MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

  • Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

  • United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

  • Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

  • Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

  • United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

  • ATS to Host Fourth Quarter Earnings Call Thursday May 28, 2026, at 8:30 a.m. Eastern

  • Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference

  • United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

  • Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

  • Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference

  • Will ATS (ATS) Beat Estimates Again in Its Next Earnings Report?

  • Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

  • MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

  • ATS (OTCMKTS:ATSAF) Shares Cross Above Fifty Day Moving Average – Here’s What Happened